IShares Genomics Valuation
| IDNA Etf | USD 22.80 0.07 0.31% |
At this time, the entity appears to be fairly valued. iShares Genomics Imm retains a regular Real Value of $22.97 per share. The prevalent price of the entity is $22.8. Our model calculates the value of iShares Genomics Imm from evaluating the entity fundamentals such as Net Asset of 170.27 M, number of employees of 403, and Beta of 1.21 as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that IShares Genomics' price fluctuation is very steady at this time. Calculation of the real value of iShares Genomics Imm is based on 3 months time horizon. Increasing IShares Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since IShares Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IShares Etf. However, IShares Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.8 | Real 22.97 | Hype 22.79 | Naive 23.05 |
The real value of IShares Etf, also known as its intrinsic value, is the underlying worth of iShares Genomics Imm ETF, which is reflected in its stock price. It is based on IShares Genomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of IShares Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of iShares Genomics Immunology helps investors to forecast how IShares etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of IShares Genomics more accurately as focusing exclusively on IShares Genomics' fundamentals will not take into account other important factors: Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates IShares Genomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in IShares Genomics and how it compares across the competition.
About IShares Genomics Valuation
The etf valuation mechanism determines IShares Genomics' current worth on a weekly basis. Our valuation model uses a comparative analysis of IShares Genomics. We calculate exposure to IShares Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of IShares Genomics's related companies.The fund generally will invest at least 80 percent of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Genomics Immunology is traded on NYSEARCA Exchange in the United States.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Genomics Immunology. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.